Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma
Yaya Chu, Meijuan Tian, Uksha Saini, Jessica Ayala-Cuesta, Kayleigh Klose, Alyssa S. Mendelowitz, Keira Foley, M. Fevzi Özkaynak, Wen Luo, Timothy P. Cripe, Dean A. Lee, Kevin A. Cassady, Mitchell S. Cairo
Abstract
< 0.05) secretion against NB cells. Furthermore, the combination of C021 and anti-ROR1-CAR-NK cells significantly extended the survival of human NB xenografted NSG mice compared to controls (mock NK, ROR1-CAR-NK, C134, C021, C134+ROR1-CAR-NK, and C021+mock NK). Our results suggest that cytokine-secreting oncolytic virus in combination with CAR-NK cells is a novel, effective immunotherapeutic approach for high-risk NB.
Topics & Concepts
Oncolytic virusEx vivoImmunotherapyVirusCancer researchVirologyBiologyIn vivoImmunologyImmune systemBiotechnologyNeuroblastoma Research and TreatmentsCAR-T cell therapy researchVirus-based gene therapy research